American Journal of Microbiological Research
ISSN (Print): 2328-4129 ISSN (Online): 2328-4137 Website: Editor-in-chief: Apply for this position
Open Access
Journal Browser
American Journal of Microbiological Research. 2018, 6(3), 94-114
DOI: 10.12691/ajmr-6-3-5
Open AccessArticle

Multi Epitopes Vaccine Prediction against Severe Acute Respiratory Syndrome (SARS) Coronavirus Using Immunoinformatics Approaches

Yassir A. Almofti1, , Khoubieb Ali Abd-elrahman2, Sahar Abd Elgadir Gassmallah3 and Mohammed Ahmed Salih4

1Department of Biochemistry and Molecular Biology, College of Veterinary Medicine, University of Bahri, Khartoum, Sudan

2Department of pharmaceutical technology, College of Pharmacy, University of Medical Science and Technology (MUST) Khartoum, Sudan

3Department of Medical laboratory, Sudan University of Science and Technology, Khartoum, Sudan

4Department of Bioinformatics, Africa city of Technology, Khartoum, Sudan

Pub. Date: July 21, 2018

Cite this paper:
Yassir A. Almofti, Khoubieb Ali Abd-elrahman, Sahar Abd Elgadir Gassmallah and Mohammed Ahmed Salih. Multi Epitopes Vaccine Prediction against Severe Acute Respiratory Syndrome (SARS) Coronavirus Using Immunoinformatics Approaches. American Journal of Microbiological Research. 2018; 6(3):94-114. doi: 10.12691/ajmr-6-3-5


Efforts for developing vaccine against Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) is crucial in prevention of SARS re-emergence. The global outbreak of SARS was contained since 2003. However concerns remain over the possibility of future recurrences, especially with recent reports of laboratory-acquired infections and the presence of sporadic cases, raising a serious concern. SARS-CoV spike S protein (1255aa) is an important target in developing safe and effective vaccines. In this study multiple bio-informatics and immuno-informatics implementation tools from NCBI and IEDB were used for epitopes prediction from spike S protein. The predicted epitopes were further assessed for population coverage against the whole world population. Our results demonstrated that the epitopes 38-RGVYYPDEI-46, 200-YQPIDVVRD-208 and 388-VVKGDDVRQ-396 elicit and stimulate B cell since they got higher score in Emini and Kolaskar and tongaonker software. For T-cell: the epitopes 47-FRSDTLYLT-55, 195-YVYKGYQPI-203 and 880-FAMQMAYRF-888 were found to interact with both MHC-1 and MHC-II alleles. Moreover 851-MIAAYTAAL-859 showed higher affinity to MHC-1 alleles while 782-FNFSQILPD-790 interacted only with MHC-II alleles. The population coverage epitope set for MHC-1 and MHC-II predicted epitopes was 82.16% and 99.97% respectively. All predicted epitopes against T cell (MHC-I/MHC-II) demonstrated strong potentiality as promising peptides vaccine with population coverage epitope set against the whole world of 100%. Taken together eight epitopes were proposed to interact with B and T cells and act as peptide vaccine against SARS-CoV virus. In vitro and in vivo studies are recommended to prove the effectiveness of these epitopes as a peptide vaccine.

SARS NCBI IEDB Insilico prediction Immunoinformatics

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


Figure of 4


[1]  Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, Zou W, Zhan J, Wang S, Xie Z, Zhuang H, Wu B, Zhong H, Shao H, Fang W, Gao D, Pei F, Li X, He Z, Xu D, Shi X, Anderson VM, Leong AS. Multiple organ infection and the pathogenesis of SARS. J Exp Med 2005 Aug 1; 202(3):415-24. Epub 2005 Jul 25.
[2]  Fouchier RA, Kuiken T, Schutten M, van Amerongen G, van Doornum GJ, van den Hoogen BG, Peiris M, Lim W, Stöhr K, Osterhaus AD. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 2003 May 15; 423(6937):240.
[3]  WHO website: Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 Accessed 2004 April 21.
[4]  Orellana C. Laboratory-acquired SARS raises worries on biosafety. Lancet Infect Dis 2004; 4(2):64.
[5]  Normile D. Infectious diseases. Mounting lab accidents raise SARS fears. Science 2004; 304 (5671): 659-61.
[6]  Normile D. Infectious diseases. SARS experts want labs to improve safety practices. Science 2003; 302 (5642):31.
[7]  Lanying Du, Guangyu Zhao, Yongping Lin, Chris CS Chan, Yuxian He, Shibo Jiang, Changyou Wu, Dong-Yan Jin, Kwok-Yung Yuen, Yusen Zhou and Bo-Jian Zheng. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes increase T cell responses and provide protection against SRAS-CoV infection. Vaccine 2008 Mar 20; 26(13): 1644-1651.
[8]  Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005; 310 (5748): 676-9.
[9]  Tong TR. SARS infection control. Lancet 2003 Jul 5; 362(9377):76; author reply 76-7.
[10]  Ho PL, Tang XP, Seto WH. SARS: hospital infection control and admission strategies. Respirology 2003 Nov; 8 Suppl:S41-5.
[11]  Fiona Fleck. SARS virus returns to China as scientists race to find effective vaccine. Bull World Health Organ 2004 Feb; 82(2): 152-153.
[12]  Marshall E and M Enserink. Caution urged on SARS vaccines. Science 2004; 303: 944.
[13]  Rota PA, MS Oberste, SS Monroe, WA Nix, R Campagnoli, JP Icenogle, S Penaranda, B Bankamp, K Maher, MH Chen, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003; 300:1394.
[14]  Marra MA, SJ Jones, CR Astell, RA Holt, A Brooks-Wilson, YS Butterfield, J Khattra, JK Asano, SA Barber, SY Chan, et al. The genome sequence of the SARS-associated coronavirus. Science 2003; 300:1399.
[15]  Qin E, Q Zhu, M Yu, B Fan, G Chang, B Si, B Yang, W Peng, T Jiang, B Liu, et al. A complete sequence and comparative analysis of a SARS-associated virus (isolate BJ01). Chin. Sci. Bull 2003; 48: 941.
[16]  He Y, Lu H, Siddiqui P, Zhou Y, Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 2005 Apr 15; 174(8):4908-15.
[17]  Babcock GJ, DJ Esshaki, WD Thomas Jr, DM Ambrosino. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J. Virol 2004; 78: 4552.
[18]  Yee-Joo Tan, Eileen Teng, Shuo Shen, Timothy H. P. Tan, Phuay-Yee Goh, Burtram C. Fielding, Eng-Eong Ooi, Hwee-Cheng Tan, Seng Gee Lim, and Wanjin Hong. A novel Severe Acute Respiratory Syndrome Coronavirus Protein, U274, is transported to the cell surface and undergoes endocytosis. J Virol 2004 Jul; 78 (13): 6723-6734.
[19]  Saif L J. Coronavirus immunogens. Vet. Microbiol 1993; 37: 285.
[20]  Wong SK, W Li, MJ Moore, H Choe, M Farzan. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin converting enzyme 2. J. Biol. Chem 2004; 279: 3197.
[21]  Xiao X, S Chakraborti, AS Dimitrov, K Gramatikoff, DS Dimitrov. The SARS-CoV S glycoprotein: expression and functional characterization. Biochem. Biophys. Res. Commun 2003; 312: 1159.
[22]  Sui J, W Li, A Murakami, A Tamin, LJ Matthews, SK Wong, MJ Moore, AS Tallarico, M Olurinde, H Choe, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl. Acad. Sci. USA 2004; 101: 2536.
[23]  Godet M, Grosclaude J, Delmas B, Laude H. Major receptor-binding and neutralization determinants are located within the same domain of the transmissible gastroenteritis virus (coronavirus) spike protein. J Virol 1994 Dec;68(12):8008-16.
[24]  He Y, Y Zhou, S Liu, Z Kou, W Li, M Farzan, S Jiang. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem. Biophys. Res. Commun 2004; 324: 773
[25]  Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA 2004; 101 (26): 9804-9.
[26]  Xiong S, Wang YF, Zhang MY, Liu XJ, Zhang CH, Liu SS, et al. Immunogenicity of SARS inactivated vaccine in BALB/c mice. Immunol Lett 2004; 95: 139-43.
[27]  He Y, Zhou Y, Siddiqui P, Jiang S. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem Biophys Res Commun 2004; 325: 445-52.
[28]  Chou TH, Wang S, Sakhatskyy PV, Mboudoudjeck I, Lawrence JM, Huang S, et al. Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology 2005; 334: 134-43.
[29]  Qu D, Zheng B, Yao X, Guan Y, Yuan ZH, Zhong NS, et al. Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. Vaccine 2005; 23: 924-31.
[30]  Tseng C-T, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE 2012; 7 (4): e35421.
[31]  Zhou Z, Post P, Chubet R, Holtz K, McPherson C, et al. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine 2006; 24: 3624-3631.
[32]  Deming D, Sheahan T, Heise M, Yount B, Davis N, et al. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Medicine 2006; 3: 2359-2375.
[33]  Yasui F, Kai C, Kitabatake M, Inoue S, Yoneda M, et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol 2008; 181: 6337-6348.
[34]  Kong WP, Xu L, Stadler K, Ulmer JB, Abrignani S, Rappuoli R, et al. Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene–based and inactivated virus immunization. J Virol 2005; 79 (22): 13915-23.
[35]  Du L, He Y, Wang Y, Zhang H, Ma S, Wong CK, et al. Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines. Virology 2006; 353 (1): 6-16.
[36]  Wang D and Lu J. Glycan arrays lead to the discovery of autoimmunogenic activity of SARS-CoV. Physiol Genomics 2004; 18: 245-8.
[37]  National Center for Biotechnology Information, NCBI.
[38]  Hall T. A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symposium Series, Vol. 41 (1999), pp. 95-98. Key: citeulike: 691774.
[39]  Immune Epitope Database (IEDB) analysis.
[40]  Larsen JE, Lund O, Nielsen M. Improved method for predicting linear B-cell epitopes. Immunome Res 2006; 2 (1): 2.
[41]  Emini E A, J V Hughes, D S Perlow, and J Boger. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol 1985 Sep; 55(3): 836-839.
[42]  Kolaskar AS and Tongaonkar PC. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett 1990; 276 (1-2): 172-174.
[43]  Immune Epitope DataBase, IEDB.
[44]  Immune Epitope Database (IEDB) MHC-I prediction tool.
[45]  Kim Y, Ponomarenko J, Zhu Z, Tamang D, Wang P; et al. Immune epitope database analysis resource. Nucleic Acids Res 2012; 40: W525-530
[46]  Nielsen M, Lundegaard C, Worning P, Lauemøller SL, Lamberth K, et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 2003; 12: 1007-1017.
[47]  Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, et al. NetMHC-3.0: Accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 2008; 36: 509-512.
[48]  Peters B and Sette A. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 2005; 6:132.
[49]  Abu-haraz AH, Abd-elrahman KA, Ibrahim MS, Hussien WH, Mohammed MS, et al. Multi epitope peptide vaccine prediction against Sudan Ebola virus using immuno-informatics approaches. Adv Tech Biol Med 2017; 5: 203.
[50]  Sidney J, Assarsson E, Moore C, Ngo S, Pinilla C, et al. Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res 2008; 4: 2.
[51]  Immune Epitope Database (IEDB) MHC-II prediction tool.
[52]  Wang P, Sidney J, Dow C, Mothé B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 2008; 4 (4): e1000048.
[53]  Immune Epitope Database (IEDB) population coverage prediction tool.
[54]  Raptor X protein structure prediction server.
[55]  Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. UCSF Chimera a visualization system for exploratory research and analysis. J Comput Chem 2004; 25: 1605-1612.
[56]  Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJ. The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc 2015 Jun; 10(6):845-58. Epub 2015 May 7
[57]  Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007; 6 (5): 404-14. PMID: 17473845.
[58]  Yang ZY, WP Kong, Y Huang, A Roberts, BR Murphy, K Subbarao, GJ Nabel. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004; 428: 561.
[59]  Bisht H, A Roberts, L Vogel, A Bukreyev, PL Collins, BR Murphy, K Subbarao, B Moss. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. USA. 2004; 101: 6641.
[60]  Black M, Trent A, Tirrell M, Olive C. Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists. Expert Rev Vaccines 2010; 9: 157-173.
[61]  Sesardic D. Synthetic peptide vaccines. J Med Microbiol 1993; 39: 241-242.
[62]  Pang H, Y Liu, X Han, Y Xu, F Jiang, D Wu, X Kong, M Bartlam, Z Rao. Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine. J. Gen. Virol 2004; 85: 3109-31.